Arbutus Biopharma Corporation (NASDAQ:ABUS) went up by 6.36% during the previous trading session, and it is maintaining the win ahead of Monday’s trading session. The share price of the Biotechnology giant went up by $1.84 to trade ended Monday trading at $1.73. This is up from the $1.73 price recorded on Friday’s trading session. Its performance from the start of the year has also been negative, with ABUS down by -33.81% year-to-date.
Arbutus Biopharma Corporation (ABUS) started the day trading at $1.69 and recorded an intraday high of $1.95. It also recorded an intraday low of $1.67 during Monday’s trading session. Arbutus Biopharma Corporation is a very active stock that recorded a trading volume that is less than -24.12% of the average daily trading volume on Monday. The stock’s trading volume on Monday was 990970, which is less than -24.12 of the total average daily trading volume of 1.23 million.
Arbutus Biopharma Corporation (NASDAQ:ABUS) 2020 Performance Impressive
The increase in ABUS’s stock price on Monday saw its overall performance boost over the past few months. We can quantify the performance of the stock so far this year using a few metrics. The 52-week high price of ABUS currently stands at $3.66, which is higher than the current trading price of the stock by 49.73%. However, ABUS’s current trading price is -124.39% lower than the 52-week low price of $0.82. In terms of trading volume, Arbutus Biopharma Corporation currently experienced healthy participation during the last trading session. 990970 shares of Arbutus Biopharma Corporation were traded on the stock exchange on Monday, which is less than -24.12% of the 1.23 million average trading volume of the stock.
The performance of the stock has been positive over the past year. ABUS’s performance over the past one year has seen it surge by 26.03%, while the stock has gone down by -23.01% in the last six months. The quarterly performance of ABUS currently stands at 29.58%, and it is down by 0.00% in the last month. The only negative figure was from the weekly performance, which currently reads -10.02%. At the time of writing ABUS’s report, the company has a total market cap of $120.30M, making it one of the largest publicly-traded companies in the world.Arbutus Biopharma Corporation also has over 80 employees all over the world.
ABUS Insider Activities
For Arbutus Biopharma Corporation, insiders hold 38.70% of all company shares. The insider transactions over the past six months are down by 0.00%. During that period, insiders bought 0 shares in 0 transactions. In that same period, insiders sold 0 of their shares in 0 transactions. After these transactions, insiders at Arbutus Biopharma Corporation now hold 20.8M shares, which is over 35.04% of the total company stocks. Institutional investors currently hold a large chunk of the ABUS shares, as they control 30.16% of the company’s total stock.
ABUS Fundamental Analysis
For Arbutus Biopharma Corporation, the stock’s diluted earnings per share (EPS) stands at -2.68. In the coming year, analysts expect the EPS to be -0.85. The stock’s EPS growth this year is -137.80%, -9.90% in the previous five years. In terms of revenue, Arbutus Biopharma Corporation’s quarterly sales (YOY) is shrinking at -0.23, which is higher than the average annual revenue of -9.90% over the past half a decade.
The Return on Investment (ROI) on Arbutus Biopharma Corporation’s stock currently stands at 203.20%.
ABUS Analysts Prediction
and B. Riley FBR reiterate their Buy position on the stock ($7 and $3).
B. Riley FBR and Chardan Capital Markets also believe that Arbutus Biopharma Corporation’s stock is outperforming at the moment. ABUS received a positive rating from B. Riley FBR, which set a price target of $11.50-$9 for the stock.
ABUS Technical Analysis
The Simple Moving Average (SMA) is one of the most powerful technical indicators. The 20-day Simple Moving Average of ABUS currently stands at -11.55%, while the SMA50 is 17.21%. The biggest one is the SMA200, which is currently reading -4.87% ahead of Monday’s trading session. The Relative Strength Index of this stock is 48.89.